



POSTER PRESENTATION

Open Access

Naïve CD8+ T cells from ART respond to primary vaccination against autologous HIV-1 antigen

Kellie N Smith^{1*}, Robbie B Mailliard², Weimin Jiang²

From 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID)
Marseille, France. 23-25 May 2012

Introduction

Antiretroviral therapy (ART) decreases HIV-1 viremia and AIDS-associated mortality. Despite this, HIV infected patients are unable to clear virus during treatment interruption due to insufficient cytotoxic T cell (CTL) activity against the autologous reservoir. It is unclear if naïve T cells from patients on ART can respond to immunotherapies that induce CTL specific for their own, unique virus. Unfortunately, late-evolving virus and the ART reservoir contain escape epitope variants that confer a lack of CTL control. We hypothesize that a dendritic cell (DC)-based immunotherapy during ART can induce CTL capable of eliminating the autologous reservoir, despite their failure to do so during natural infection.

Materials and methods

We use a naïve T cell flow cytometry panel to evaluate changes in the naïve CD4+:CD8+ T cell ratio before seroconversion, during untreated infection, and after ART in an HIV infected subject. We then use this panel to isolate naïve CD4+ and CD8+ T cells from this patient during ART and from HIV negative donors. These purified naïve T cells are then used in an in vitro model of dendritic cell (DC) vaccination at their in vivo ratios to induce primary IFNγ-producing CTL against autologous HIV-1 Gag, Env, and Nef peptide antigens derived from ART.

Results

Although partial immune reconstitution occurs during ART, we observed a disproportionate recovery in the naïve CD4+:CD8+ T cell ratio compared to pre-infection. Despite this, we show that naïve CD4+ and CD8+ T cells from ART, when primed at their skewed in vivo

ratio against late-acquired, “escape” epitope variants, differentiate into IFNγ-producing CTL comparable to those induced in pre-seroconversion T cells. Additionally, we show that primary CTL responses induced during ART are comparable to those observed in HIV negative donors. Figure 1.




Figure 1

* Correspondence: kns27@pitt.edu

¹University of Pittsburgh School of Medicine, Department of Molecular Virology and Microbiology, Pittsburgh, USA

Full list of author information is available at the end of the article

Conclusion

These data indicate that, despite a disproportionate recovery in the naïve CD4+:CD8+ T cell ratio, DC vaccination of naïve T cells from ART can induce CTL specific for autologous “escape” HIV-1 variants, and that these naïve T cells can respond to primary vaccination at a level similar to pre-infection. These data support the use of DC immunotherapies in HIV infected patients on ART.

Author details

¹University of Pittsburgh School of Medicine, Department of Molecular Virology and Microbiology, Pittsburgh, USA. ²University of Pittsburgh Graduate School of Public Health, Department of Infectious Diseases and Microbiology, USA.

Published: 25 May 2012

doi:10.1186/1742-4690-9-S1-P16

Cite this article as: Smith et al.: Naïve CD8+ T cells from ART respond to primary vaccination against autologous HIV-1 antigen. *Retrovirology* 2012 **9**(Suppl 1):P16.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

